Literature DB >> 2115448

A thirty year journey in the polyol pathway.

J H Kinoshita1.   

Abstract

The development of the concept that aldose reductase (AR) is involved in diabetic complications is presented from its early beginning when Dr Van Heyningen first found polyols in sugar cataracts in 1959. The involvement of the polyol theory of sugar cataract is described. The prevention of sugar cataract formation by aldose reductase inhibitors dramatically demonstrates the role of this enzyme in sugar-induced cataracts. The possibility of AR involvement of other diabetic complications was an obvious extension of the polyol theory. The use of AR inhibitors in preventing diabetic changes in nerve and retina in animals strongly suggest that AR may play a role in the development of other diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2115448     DOI: 10.1016/0014-4835(90)90096-d

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  35 in total

Review 1.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 2.  Ocular complications of diabetes mellitus.

Authors:  Nihat Sayin; Necip Kara; Gökhan Pekel
Journal:  World J Diabetes       Date:  2015-02-15

Review 3.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.

Authors:  Ravichandran Ramasamy; Ira J Goldberg
Journal:  Circ Res       Date:  2010-05-14       Impact factor: 17.367

Review 4.  Multitargeting by curcumin as revealed by molecular interaction studies.

Authors:  Subash C Gupta; Sahdeo Prasad; Ji Hye Kim; Sridevi Patchva; Lauren J Webb; Indira K Priyadarsini; Bharat B Aggarwal
Journal:  Nat Prod Rep       Date:  2011-10-06       Impact factor: 13.423

Review 5.  Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?

Authors:  Kenneth H Gabbay
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

6.  Effects of galactose feeding on aldose reductase gene expression.

Authors:  R R Wu; P A Lyons; A Wang; A J Sainsbury; S Chung; T N Palmer
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes.

Authors:  H P Hammes; H J Federoff; M Brownlee
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

8.  Aldose reductase-catalyzed reduction of aldehyde phospholipids.

Authors:  Sanjay Srivastava; Matthew Spite; John O Trent; Matthew B West; Yonis Ahmed; Aruni Bhatnagar
Journal:  J Biol Chem       Date:  2004-10-01       Impact factor: 5.157

9.  Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs).

Authors:  Vidadala Ramasubba Rao; Puppala Muthenna; Gundeti Shankaraiah; Chandrasekhar Akileshwari; Kothapalli Hari Babu; Ganji Suresh; Katragadda Suresh Babu; Rotte Sateesh Chandra Kumar; Kothakonda Rajendra Prasad; Potharaju Ashok Yadav; J Mark Petrash; Geereddy Bhanuprakash Reddy; Janaswamy Madhusudana Rao
Journal:  Eur J Med Chem       Date:  2012-09-26       Impact factor: 6.514

10.  Design of an amide N-glycoside derivative of β-glucogallin: a stable, potent, and specific inhibitor of aldose reductase.

Authors:  Linfeng Li; Kun-Che Chang; Yaming Zhou; Biehuoy Shieh; Jessica Ponder; Adedoyin D Abraham; Hadi Ali; Anson Snow; J Mark Petrash; Daniel V LaBarbera
Journal:  J Med Chem       Date:  2013-12-23       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.